Summarised by Centrist
In the US, Pfizer has agreed to settle a class action lawsuit and will pay out on more than 10,000 claims around its discontinued heartburn drug Zantac and its alleged links to cancer.
Other Zantac makers like GSK and Sanofi have also reached agreements to settle similar lawsuits.
The lawsuits accuse the pharma giant of concealing cancer risks associated with the heartburn drug, in a deal reportedly worth up to $250m USD.
In 2004, Pfizer received FDA approval to market over-the-counter versions of Zantac in the US.
The US FDA confirmed samples of Zantac were found to contain a probable human carcinogen called NDMA in 2020 and ordered all versions of the drug off the market.
The popular antacid medication has been owned by various drugmakers over its 30-year history.
